Crinetics to present up to 2-year PATHFNDR open-label extension data on oral acromegaly drug Palsonify at ENDO 2026

CRINETICS PHARMACEUTICALS, INC.

CRINETICS PHARMACEUTICALS, INC.

CRNX

0.00
  • Crinetics outlined six ENDO 2026 presentations, led by longer-term open-label extension results for PALSONIFY (paltusotine) in acromegaly.
  • Results will be presented June 13-16, 2026 in Chicago, including data extending to two years from PATHFNDR-1 and PATHFNDR-2.
  • The PALSONIFY readout is positioned to reinforce durable disease control with a safety profile consistent with longer-term use, supporting commercial uptake post U.S. and E.U. launches.
  • Atumelnant oral presentations will disclose full Phase 2 congenital adrenal hyperplasia results, highlighting potential to reduce steroid burden while maintaining hormonal control.
  • Additional atumelnant updates in ACTH-dependent Cushing’s syndrome will present interim findings supporting a block-and-replace strategy, informing late-stage development decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020455PRIMZONEFULLFEED9730137) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.